4F, BUILDING C14, NO. 218, XINGHU STREET, JIANGSU, F4
Resignation of Officer
NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager
Announces that Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Achieves Milestone in Collaboration for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates
Reports Six Months 2026 Financial Results and Provides Corporate Updates
Reports Unaudited Cash and Cash Equivalents of US$127.9 Million as of June 30, 2026
Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types
Announces Pricing of US$70.0 Million Public Offering of ADSs
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Statement of Changes in Beneficial Ownership
Amended Notice of Proposed Sale of Securities
Notice of Proposed Sale of Securities
Correspondence
Submission Upload